Mithramycin

DRUG3 trials

Sponsors

National Cancer Institute (NCI)

Conditions

Breast CancerEsophageal CancerEsophageal NeoplasmsEwing SarcomaGastrointestinal NeoplasmsLung CancerLung NeoplasmsMesothelioma

Phase 1

Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma

TerminatedNCT01610570

National Cancer Institute (NCI)Ewing Sarcoma, Sarcoma

Start: 2012-05-10End: 2014-05-21Updated: 2018-03-02

Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases

TerminatedNCT02859415

National Cancer Institute (NCI)Esophageal Neoplasms, Lung Neoplasms, Mesothelioma +2

Start: 2019-08-08End: 2021-12-01Updated: 2022-04-05

Phase 2

Mithramycin for Lung, Esophagus, and Other Chest Cancers

TerminatedNCT01624090

National Cancer Institute (NCI)Breast Cancer, Esophageal Cancer, Gastrointestinal Neoplasms +2

Start: 2012-09-06End: 2019-09-27Updated: 2019-12-30